KLRK1 and cancer: NK cells exert their antitumor activity through the binding of their activating receptors, such as NKp46, NKp30, NKp44, NKG2D, and killer cell immunoglobulin-like receptors (KIRs), to NK cells ligands expressed on the surface of cancer cells (19).